Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 10Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Recurrence 3Prostatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Skin Neoplasms 1Salivary Gland Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Neoplasms 1Nasopharyngeal Neoplasms 1

Interventions

Cytarabine 358Cyclophosphamide 241Azacitidine 213fludarabine phosphate 199venetoclax 198fludarabine 196Busulfan 148Decitabine 132Mycophenolic Acid 123Whole-Body Irradiation 122Peripheral Blood Stem Cell Transplantation 118Tacrolimus 115Granulocyte Colony-Stimulating Factor 104Idarubicin 100Filgrastim 100Melphalan 89Cyclosporine 89Methotrexate 83Daunorubicin 76Antilymphocyte Serum 75Etoposide 73Mitoxantrone 67Clofarabine 67Gemtuzumab 59Stem Cell Transplantation 55Thiotepa 51Cladribine 46Injections 45Specimen Handling 44thymoglobulin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Acute × NVP-BKM120 × Clear all
NCT01396499 2016-11-01

Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

M.D. Anderson Cancer Center

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡